Journey Medical (DERM) EV to CFO (2021 - 2026)

Journey Medical (DERM) has reported EV to CFO for 6 consecutive years, with 97.47 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO rose 37.51% year-over-year to 97.47; the trailing twelve-month figure through Jun 2026 stood at 22.56 (up 58.45% YoY), and the FY2025 full-year result was 11.17, down 71.06% from the prior year.
• EV to CFO slipped to 97.47 in Q2 2026 per DERM's latest filing, from 34.67 in the prior quarter.
• Across five years, EV to CFO topped out at 47.9 in Q1 2022 and bottomed at 155.97 in Q2 2025.
• Historically, EV to CFO has averaged 20.9 across 5 years, with a median of 6.47 in 2022.
• The widest YoY moves for EV to CFO: up 670.22% in 2024, down 5994.62% in 2024.
• Over 5 years, EV to CFO stood at 0.43 in 2022, then sank by 987.13% to 4.7 in 2023, then jumped by 670.22% to 26.78 in 2024, then slumped by 182.56% to 22.11 in 2025, then sank by 340.88% to 97.47 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 97.47, 34.67, and 22.11 for Q2 2026, Q1 2026, and Q4 2025 respectively.